

## Curriculum vitae

### Dr. Franz Enzmann

- 1938 born in Saaz, Sudetenland
- 1966 PhD at the University of Heidelberg; Prof. Schildknecht  
"Structure elucidation by hydrated electrons"
- 1967 McBean Fellowship, Stanford Research Institute, California, Prof. Folkers  
Natural Product Chemistry, Neuroendocrinology, Muscular Dystrophy: first application  
of Ubiquinone Q10 at the Stanford Children's Hospital in children with Muscular  
Dystrophy
- 1968 Research Associate at the Institute for Biochemical Research, Univ. of Texas at  
Austin; Prof. Folkers, search for Hypothalamus Hormones
- 1969 Structure elucidation and synthesis of the first Hypothalamus Hormone **TRH**  
(Thyroid Hormone Releasing Hormone) led 1977 to the Nobel Prize in Medicine  
for Prof. A.V. Schally  
Van Meter Price of the American Thyroid Association together with C. Bowers,  
K.F. Folkers and A.V. Schally
- 1969 Pharma Biochemistry at Hoechst AG: isolation, purification and elucidation of Insulin,  
Hypothalamus- and Pituitary Hormones, Thymus Peptides and Ubiquinone Q10
- 1973 Transfer to the Medical Department Hoechst, trained for two years at the Intern  
Department of the Univ. Frankfurt, Prof. Schöffling, in Metabolic- and Neuroendocrine  
Diseases. Therapeutic potential of Ubiquinone Q10.  
First meeting with Prof. Rolf Luft, Diabetologist, Endokrinologist and the  
**"Father of Mitochondrial Medicine"**
- 1980 Attracted by Gene-Technology I changed to Eli Lilly Germany to set up the  
Business Unit Diabetology and Endocrinology to test and introduce Human Insulin  
and Growth Hormone
- 1984 Accepted the offer to become Head of Research and Development at Byk Gulden,  
Konstanz. Focus on Pulmunology, Cardiology and Gastro-Enterology. Setting up  
a Gene-Technology Unit to develop Human Lung Surfactant for ARDS.  
Relaunch of a Diagnostic Unit
- 1988 Bissendorf Peptide offered me to set up a pharmaceutical company specializing  
in peptide drugs produced by gene technology  
Co-Founding the "Niedersächsische Institut für Peptidforschung";  
Director: Prof. Forssmann.
- 1992 Foundation of MSE Pharmazeutika GmbH, focussing on Mitochondrial Medicine as  
basis for all degenerative inflammatory diseases. Key mitotropic compounds are:  
Ubiquinone Q10, B<sub>2</sub>, B<sub>3</sub>, Mg<sup>++</sup>, Carnitine - ω-3 Fatty Acids – SOD, GPx, KAT, Vit. C  
Ubiquinol Q10, B<sub>12</sub> – Se, Zn, Cu, Mn, Cr<sup>III</sup>.
- 1998 Foundation of the International Mitochondrial Medicine Association - IMMA

Initiated Clinical Trials over the past 5 years:

Resuscitation	University Dresden	Circulation 2004
Endothel Protection	University Tübingen	Cardiology 2005
Migrain	University Zurich	Neurology 2005
Parkinson	Multicenter Dresden	Arch. Neurology 2007
PSP	University Marburg	Movement Disorders 2008
Tinnitus	Charité Berlin	in press
Protection from contrastmedia side effects		
ICQA – 2012	Sevilla	
AOA1	Hôpital de La Salpêtrière, Paris	in progress

Memberships:

Deutsche Endokrinologie Gesellschaft  
Deutsche Diabetes Gesellschaft  
International Q10 Association  
International Mitochondrial Medicine Association  
Deutsche Parkinson Gesellschaft  
Autismus Deutschland  
PSP Deutschland

IMMA ( International Mitochondria Medicine Association)  
Dr. Franz Enzmann  
Am Wingertsberg 3 B  
61348 Bad Homburg

[f.h.enzmann@mse-pharma.de](mailto:f.h.enzmann@mse-pharma.de)